Lupin Partners With SteinCares To Supply Biosimilar in LATAM
ECONOMY & POLICY

Lupin Partners With SteinCares To Supply Biosimilar in LATAM

Global pharmaceutical major Lupin Limited has entered into a licence and supply agreement with SteinCares, a leading Latin American speciality healthcare firm, for the commercialisation of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.

As per the agreement, SteinCares will manage all regulatory submissions, registrations, and commercial activities, while Lupin will be responsible for manufacturing the biosimilar.

Ranibizumab is a recombinant humanised monoclonal antibody fragment (IgG1) that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat several retinal conditions including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularisation (mCNV).

Dr Cyrus Karkaria, President of Biotechnology at Lupin, said, “This partnership underscores our commitment to making advanced retinal therapies accessible in Latin America and improving patients’ quality of life.”

Sebastián Katz, Chief Strategy Officer at SteinCares, added, “Our collaboration with Lupin bolsters our leadership in the biosimilar space and helps bring affordable, high-quality treatments to healthcare systems across the region.”

This partnership aims to enhance the reach of cost-effective, advanced ophthalmic treatments across Latin America, aligning with both companies’ missions to deliver impactful healthcare solutions.

Global pharmaceutical major Lupin Limited has entered into a licence and supply agreement with SteinCares, a leading Latin American speciality healthcare firm, for the commercialisation of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.As per the agreement, SteinCares will manage all regulatory submissions, registrations, and commercial activities, while Lupin will be responsible for manufacturing the biosimilar.Ranibizumab is a recombinant humanised monoclonal antibody fragment (IgG1) that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat several retinal conditions including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularisation (mCNV).Dr Cyrus Karkaria, President of Biotechnology at Lupin, said, “This partnership underscores our commitment to making advanced retinal therapies accessible in Latin America and improving patients’ quality of life.”Sebastián Katz, Chief Strategy Officer at SteinCares, added, “Our collaboration with Lupin bolsters our leadership in the biosimilar space and helps bring affordable, high-quality treatments to healthcare systems across the region.”This partnership aims to enhance the reach of cost-effective, advanced ophthalmic treatments across Latin America, aligning with both companies’ missions to deliver impactful healthcare solutions.

Next Story
Real Estate

AI: The New Recruit

From getting ideas to evaluating designs, presenting concepts to clients and tracking projects, artificial intelligence (AI) is helping architects work better and faster.“AI allows architects to spend more time doing what only they can do: think critically, synthesise complexity and design with intent,” says Dikshu C Kukreja, Managing Principal, CP Kukreja Architects. “Every minute reclaimed from repetitive processes can be invested in creativity, contextual understanding, interdisciplinary collaboration and innovation – the qualities that define meaningful architecture.”To read the ..

Next Story
Real Estate

Redevelopment 2.0

In 2017, Mumbai identified 160,000 ageing buildings due for structural audit. Close to half of these were in the Western Suburbs. Redeveloping the oldest and structurally weakest of these would help unlock new housing, much needed given the city’s growing population density and constant developed area of 437.7 sq km. At 30,600 people per sq km in 2024, Mumbai’s density was almost thrice that of Gurugram, and 60 per cent higher than Bengaluru’s.Essentially, Mumbai’s realty market has demand. It has capital. It has realty development potential.Fast forward to 2026. Mumbai has 1,094 regis..

Next Story
Technology

Cost intelligence will become a strategic contributor to project success

As India's construction industry accelerates its digital transformation, integrated platforms, AI and connected data are becoming essential to improving cost certainty, project efficiency and sustainability. Ravi Kumar, Sales Director – India, RIB Software India, shares how digital workflows are reshaping project planning, commercial management and decision-making across the construction value chain.India's construction sector is embracing digital technologies at an unprecedented pace. From your perspective, what are the biggest shifts driving this transformation and how is RIB Software enab..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement